Navigation Links
Novel Technique Would Prevent Re-Clogged Arteries

Researchers at the Technion-Israel Institute of Technology are proposing a revolutionary approach to prevent the common post-balloon angioplasty problem// of restenosis (re-clogging of coronary arteries).

More than 1.2 million angioplasties were performed in the United States in 2003, according to the American Heart Association.

Angioplasty is a minimally invasive procedure, during which a tiny deflated balloon is inserted into clogged arteries and inflated to open blockages. In many cases, a stent – originally mounted on the balloon – is then positioned inside the artery, against the arterial wall. Blockages – caused not by new fatty deposits, but by tissue growth from the walls of the blood vessel – re-occur in more than one-third of patients. Such growths, which doctors relate to as they would a cancerous growth, are most often treated with “anti-proliferative” medications that prevent uncontrolled tissue growth.

Because of the site-specific nature of these growths, the drugs to treat them must be delivered only to the affected tissue. Stent manufacturers currently include such drugs in their products for slow release over a six-month period (during which time the risk for restenosis is highest). Precise control of this release process can be tricky, however, and restenosis still occurs in many patients.

The new, patented technique – developed in the Technion Department of Biomedical Engineering by Professor Noah Lotan, Dr. Sarit Sivan and Professor Uri Dinnar – begins when the patient swallows a "pro-drug" compound. Inactive by itself, this compound can be taken for as long as necessary without side effects. It is activated only when it comes into contact with a specific enzyme attached to the stent by its manufacturer. In effect, the enzyme on the stent then becomes a "pharmaceutical factory" that manufactures an active anti-proliferative drug.

According to lead researcher Lotan, the pro-drug is an amin o acid that is a safe and natural component of all proteins. When the risk of restenosis abates, patients could simply stop taking the pro-drug, and the stent would stop manufacturing the drug.

“This approach makes up a very general technological platform that can be applied for different medical problems,” said Lotan. “It has potential applications for every drug, known today or invented in the future, and could be useful for medications – including chemotherapy drugs – best administered to one very specific location in the body."

Source-Newwise
SRM
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... 4, 2017  According to the Centers for Disease Control and Prevention ... . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the month. ... health insurance regulations. ... to get a flu shot is by the end of October, according ...
Breaking Medicine Technology: